GlaxoSmithKline S.A.E
GlaxoSmithKline S.A.E. (GSK) is a leading global healthcare company headquartered in Great Britain. Founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK has established a strong presence in pharmaceuticals, vaccines, and consumer healthcare. The company operates extensively across Europe, North America, and emerging markets, focusing on innovative solutions to improve patient health. GSK's core products include prescription medicines, vaccines, and over-the-counter health products, distinguished by their commitment to research and development. Notable achievements include advancements in respiratory and HIV treatments, positioning GSK as a key player in the global pharmaceutical landscape. With a robust pipeline and a dedication to sustainability, GSK continues to drive progress in the healthcare industry.
DitchCarbon Score
How does GlaxoSmithKline S.A.E's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GlaxoSmithKline S.A.E's score of 97 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GlaxoSmithKline S.A.E, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of GSK plc, which means that any climate commitments or emissions data would be cascaded from its parent organisation. GSK plc has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and commitments to renewable energy through the RE100 initiative. These initiatives aim to significantly reduce carbon emissions across their operations, although specific reduction targets for GlaxoSmithKline S.A.E have not been detailed. As part of its climate strategy, GSK plc is committed to achieving net-zero emissions across its value chain by 2030, which includes addressing Scope 1, 2, and 3 emissions. However, the specific contributions or progress of GlaxoSmithKline S.A.E towards these targets remain unspecified. In summary, while GlaxoSmithKline S.A.E is aligned with its parent company's ambitious climate commitments, detailed emissions data and specific reduction targets for the subsidiary are currently unavailable.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GlaxoSmithKline S.A.E is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
